Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
TRLV vs CGC: Why the Profitable U.S. Cannabis Operator Holds the Edge

TRLV vs CGC: Why the Profitable U.S. Cannabis Operator Holds the Edge

Key Takeaways

  • Tickeron AI Verdict: TRLV currently holds the edge over CGC, reflecting stronger profitability, positive cash flow, and more consistent trend positioning.
  • TRLV is a profitable U.S. multi-state operator (MSO) that became the first U.S.-based cannabis company to list on the NYSE, while CGC is a Canadian producer still working through a multi-year turnaround.
  • CGC is posting accelerating international medical sales, yet it remains unprofitable and faces meaningful share-dilution and U.S. asset-default risks.
  • TRLV generates operating profit and positive free cash flow, supported by roughly 207 retail dispensaries and about 3.5 million square feet of cultivation capacity.
  • For more context, explore CGC Major News and CGC Today's Price Move, plus TRLV Major News and TRLV Today's Price Move.
  • To see how automated strategies are navigating this market, explore the curated Trending AI Robots.

Setting the Stage for Two Cannabis Stocks

Both CGC and TRLV operate in the cannabis industry, but they occupy very different positions within it. Canopy Growth Corporation is a Canadian licensed producer with global ambitions, while Trulieve Cannabis Corp. is a U.S.-focused, vertically integrated multi-state operator. A stock comparison between the two is especially relevant now, as U.S. regulatory rescheduling reshapes the sector's access to capital and institutional investors. Traders and investors weighing exposure to cannabis may find this relative performance review useful for understanding how a domestic turnaround story and a profitable U.S. operator compare on momentum, risk, and market positioning. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Canopy Growth's Current Position

Canopy Growth Corporation is a Canadian cannabis producer selling medical and adult-use products across Canada and international markets such as Germany, Poland, the U.K., and Australia, alongside its Storz & Bickel vaporizer business. In recent market activity, CGC has traded near multi-year lows, having declined sharply over the trailing year. Its latest quarterly results showed double-digit revenue growth, led by a sharp increase in international medical cannabis sales, but earnings still missed estimates after a large non-cash fair-value charge tied to its Canopy USA assets. Sentiment has been weighed down by persistent net losses, shareholder dilution from at-the-market (ATM) equity programs, an approved share consolidation, and debt tied to U.S. affiliates in default under a forbearance arrangement. From what I see, the international growth is promising but the broader challenges remain significant.

Trulieve's Strengths in Focus

Trulieve Cannabis Corp. is a vertically integrated U.S. multi-state operator (MSO) with an established medical cannabis presence in Florida, Georgia, Pennsylvania, and West Virginia, operating roughly 207 dispensaries and about 3.5 million square feet of cultivation and processing capacity. In recent weeks, TRLV has been notable as the first U.S.-based cannabis company to list on the NYSE, a move enabled by the federal rescheduling of state-sanctioned medical cannabis. Unlike many cannabis peers, Trulieve has reported operating profit and positive free cash flow over the trailing twelve months. Sentiment has been supported by a share repurchase program and continued retail and medical expansion, positioning the company as one of the more financially stable operators in the sector. I’m watching this closely as the NYSE listing adds a layer of visibility.

Head-to-Head Comparison

The two companies differ most sharply on geography and financial health. TRLV is a U.S.-centric MSO with an established, scaled footprint in regulated medical markets and a profitable operating model. CGC is a Canadian producer pivoting toward international medical growth, still working toward positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). On growth drivers, Canopy is leaning on fast-growing European medical demand and MTL Cannabis integration, while Trulieve is expanding retail count and share buybacks. Risk profiles also contrast: CGC carries dilution, cash-burn, and default-related uncertainty around its U.S. affiliates, whereas TRLV faces state-level regulatory concentration and competition. Market sentiment currently favors the profitable, cash-generating operator over the turnaround story.

Tickeron AI Verdict

Based on observable factors, Tickeron's AI would likely favor TRLV at present. Trulieve's combination of profitability, positive free cash flow, an NYSE listing, and steadier market positioning offers a more consistent trend profile than Canopy Growth's improving but still unprofitable, diluting turnaround. While CGC retains a credible international growth catalyst, its near-term uncertainty around losses, share consolidation, and U.S. asset defaults weighs on relative stability. Accordingly, TRLV appears the more favored candidate in this stock comparison, though both names carry sector-level volatility inherent to cannabis equities. One thing that stands out is how the data consistently points to financial stability as a key differentiator right now.

Exploring Automated Strategies with Tickeron

Tickeron maintains a broad library of hundreds of AI trading bots that collectively trade thousands of different tickers. Because only the strongest, most suitable strategies for current market conditions deserve attention, Tickeron curates the top performers into its Trending AI Robots section. These bots span a wide range of trading styles, strategies, timeframes, performance statistics, and ticker universes, giving traders and investors varied ways to approach the market. Reviewing this curated list can help you identify automated approaches aligned with your objectives. I often turn to these tools when evaluating sector-specific opportunities like cannabis stocks to see what the data highlights.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CGC, TRLV

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


Momentum Indicator for CGC turns negative, indicating new downward trend

CGC saw its Momentum Indicator move below the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In 76 of the 82 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CGC turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 38 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CGC entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +10.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGC advanced for three days, in 162 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

CGC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.400) is normal, around the industry mean (6.379). P/E Ratio (-0.972) is within average values for comparable stocks, (0.548). CGC's Projected Growth (PEG Ratio) (7.200) is slightly higher than the industry average of (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.549) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. CGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -7%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -13%. AKAN experienced the highest price growth at 411%, while BFRI experienced the biggest fall at -38%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was 2% and the average quarterly volume growth was 20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 56
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 8 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a producer of medical marijuana

Industry PharmaceuticalsGeneric

Industry
Agricultural Commodities Or Milling
Address
1 Hershey Drive
Phone
+1 855 558-9333
Employees
1128
Web
https://www.canopygrowth.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.